Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC

Sponsor
Chinese University of Hong Kong
Study ID
NCT07724886
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Conventional Transurethral Resection of Bladder Tumour — PROCEDURE
    Conventional TURBT is performed by resecting the bladder tumour in a piecemeal manner with a top-down approach. The bladder tumour specimen is fragmented during the procedure and whether a complete resection has been achieved is determined by the operating surgeon's judgment intra-operatively.
  • Transurethral En Bloc Resection of Bladder Tumour — PROCEDURE
    This surgical technique resects the bladder tumour underneath the submucosal plane, and the bladder tumour can be removed in one piece.

Study Details

This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.

Key Dates

First listed
Jul 24, 2026
Start date
Jul 1, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2029
Completion
Mar 31, 2030

Study Design

Enrollment
732 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Conventional Transurethral Resection of Bladder Tumour (cTURBT)
  • Experimental: Transurethral En Bloc Resection of Bladder Tumour (ERBT)

Primary Outcome Measure

Rate of recurrence-free survival [ Time Frame: At Year 2 ]

Central Contacts

Find similar trials

Nationwide
Bladder cancer trialsOncology trialsUrology trials

Related Studies